Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

医学 卡铂 化疗 危险系数 内科学 安慰剂 外科 临床终点 卵巢癌 胃肠病学 无进展生存期 癌症 肿瘤科 泌尿科 置信区间 随机对照试验 顺铂 病理 替代医学
作者
Thomas J. Herzog,Sandro Pignata,Sharad Ghamande,Maria-Jesús Rubio,Keiichi Fujiwara,Christof Vulsteke,Deborah K. Armstrong,Jalid Sehouli,Robert L. Coleman,Hani Gabra,Giovanni Scambia,Bradley J. Monk,José Ángel Arranz,Kimio Ushijima,Rabbie K. Hanna,Claudio Zamagni,Robert M. Wenham,Antionio González-Martín,Brian M. Slomovitz,Yan Jia
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:170: 300-308 被引量:13
标识
DOI:10.1016/j.ygyno.2023.01.003
摘要

The primary purpose of this study was to determine if farletuzumab, an antifolate receptor-α monoclonal antibody, improved progression-free survival (PFS) versus placebo when added to standard chemotherapy regimens in patients with platinum-sensitive recurrent ovarian cancer (OC) in first relapse (platinum-free interval: 6-36 months) with low cancer antigen 125 (CA-125) levels.Eligibility included CA-125 ≤ 3 x upper limit of normal (ULN, 105 U/mL), high-grade serous, platinum-sensitive recurrent OC, previous treatment with debulking surgery, and first-line platinum-based chemotherapy with 1st recurrence between 6 and 36 months since frontline platinum-based treatment. Patients received investigator's choice of either carboplatin (CARBO)/paclitaxel (PTX) every 3 weeks or CARBO/pegylated liposomal doxorubicin (PLD) every 4 weeks x6 cycles in combination with either farletuzumab [5 mg/kg weekly] or placebo randomized in a 2:1 ratio. Maintenance treatment with farletuzumab (5 mg/kg weekly) or placebo was given until disease progression or intolerance.214 patients were randomly assigned to farletuzumab+chemotherapy (142 patients) versus placebo+chemotherapy (72 patients). The primary efficacy endpoint, PFS, was not significantly different between treatment groups (1-sided α = 0.10; p-value = 0.25; hazard ratio [HR] = 0.89, 80% confidence interval [CI]: 0.71, 1.11), a median of 11.7 months (95% CI: 10.2, 13.6) versus 10.8 months (95% CI: 9.5, 13.2) for farletuzumab+chemotherapy and placebo+chemotherapy, respectively. No new safety concerns were identified with the combination of farletuzumab+chemotherapy.Adding farletuzumab to standard chemotherapy does not improve PFS in patients with OC who were platinum-sensitive in first relapse with low CA-125 levels. Folate receptor-α expression was not measured in this study. (Clinical Trial Registry NCT02289950).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wxf完成签到,获得积分10
1秒前
大个的应助被开心德地采纳,获得10
1秒前
xu完成签到,获得积分10
1秒前
wq完成签到,获得积分10
1秒前
2秒前
3秒前
欢喜的非笑完成签到 ,获得积分10
3秒前
李子青发布了新的文献求助10
3秒前
3秒前
光光发布了新的文献求助10
3秒前
4秒前
CipherSage的应助被你好采纳,获得10
4秒前
4秒前
730发布了新的文献求助10
5秒前
wanci的应助被青柠味薯片采纳,获得10
5秒前
5秒前
duanzou完成签到,获得积分10
6秒前
Orange的应助被明亮飞双采纳,获得10
6秒前
7秒前
科研通AI6.4的应助被奈者CO采纳,获得100
7秒前
我是老大的应助被weihua采纳,获得30
7秒前
ding的应助被开心德地采纳,获得20
8秒前
8秒前
LuckyYu发布了新的文献求助10
9秒前
bademing完成签到,获得积分10
10秒前
long发布了新的文献求助10
10秒前
DrLee完成签到,获得积分10
10秒前
余香的应助被小卢采纳,获得10
10秒前
duanzou发布了新的文献求助10
10秒前
11秒前
完美世界的应助被金鱼采纳,获得10
11秒前
13秒前
13秒前
13秒前
小L完成签到,获得积分10
13秒前
13秒前
bbh56完成签到,获得积分10
14秒前
完美世界的应助被吱吱采纳,获得10
14秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986